enGene (NASDAQ:ENGN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.11), Zacks reports.
enGene Price Performance
ENGN stock traded up $0.06 during trading on Thursday, hitting $5.35. The stock had a trading volume of 20,299 shares, compared to its average volume of 131,513. enGene has a twelve month low of $4.42 and a twelve month high of $18.40. The company's 50-day moving average price is $6.59 and its two-hundred day moving average price is $7.13. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The stock has a market capitalization of $272.73 million, a P/E ratio of -9.22 and a beta of -0.61.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on ENGN. Raymond James started coverage on enGene in a report on Wednesday, November 27th. They issued an "outperform" rating and a $23.00 price target for the company. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Morgan Stanley lowered their price target on shares of enGene from $37.00 to $34.00 and set an "overweight" rating on the stock in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price objective on shares of enGene in a report on Tuesday. Finally, Piper Sandler initiated coverage on shares of enGene in a research report on Tuesday, February 18th. They issued an "overweight" rating and a $26.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, enGene has a consensus rating of "Buy" and a consensus price target of $25.22.
Read Our Latest Stock Report on ENGN
About enGene
(
Get Free Report)
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
See Also
Before you consider enGene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and enGene wasn't on the list.
While enGene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
